From neuraminidase inhibitors to novel mechanisms: expanding therapeutic strategies against influenza. [PDF]
Sun Y +4 more
europepmc +1 more source
Occurrence of influenza antivirals and resistance development in influenza A viruses in aquatic environments: A risk assessment. [PDF]
Söderström Lindström H +4 more
europepmc +1 more source
Detection and characterization of antiviral-resistant viruses during the influenza season of 2024-25. [PDF]
Patel MC +19 more
europepmc +1 more source
Clinical impact of baloxavir-induced PA I38T/M substitutions in diverse influenza populations: a systematic review and meta-analysis. [PDF]
Zhao Y, Fan H.
europepmc +1 more source
Influenza A (H1N1) virus infection complicated by checkpoint inhibitor pneumonitis: A case report. [PDF]
Cheng Y, Zhao H, An Y.
europepmc +1 more source
MDL-001: An Oral, Direct-Acting Broad-Spectrum Antiviral for Influenza-like Illness (ILI) and Chronic Hepatitis In Vivo. [PDF]
Woods V +15 more
europepmc +1 more source
Effectiveness of baloxavir marboxil in nonhuman primates infected with highly pathogenic avian influenza A(H7N9) virus. [PDF]
Iwatsuki-Horimoto K +8 more
europepmc +1 more source
Influenza Antiviral Prescriptions in the US Inpatient and Outpatient Settings During the 2015-2022 Influenza Seasons. [PDF]
Lee K, Basu A, Englund JA.
europepmc +1 more source
Updated A(H1N1)pdm09 influenza virus ferret infection model permits refined antiviral assessment using aerosol inhalation challenge. [PDF]
Stannard HL +12 more
europepmc +1 more source
Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database. [PDF]
Cao B, Shen M, Du C, Song Q, Ma Z.
europepmc +1 more source

